open access

Vol 69, No 5 (2018)
Original Paper
Published online: 2018-08-03
Submitted: 2018-04-24
Accepted: 2018-04-30
Get Citation

The role of the cAMP/PKA signalling pathway in the inhibitory influence of melatonin on oxytocin and vasopressin secretion from the rat hypothalamo-neurohypophysial system

Marlena Juszczak, Anna Krzyminska, Ewa Bojanowska, Magdalena Roszczyk
DOI: 10.5603/EP.a2018.0051
·
Pubmed: 30074234
·
Endokrynologia Polska 2018;69(5):560-566.

open access

Vol 69, No 5 (2018)
Original Paper
Published online: 2018-08-03
Submitted: 2018-04-24
Accepted: 2018-04-30

Abstract

Introduction: Melatonin was found to inhibit forskolin-stimulated oxytocin (OT) and vasopressin (VP) release in vitro. The purpose of the present investigation was to evaluate the contribution of the cyclic 3’,5’-adenosine monophosphate/protein kinase A (cAMP/PKA) signalling pathway in melatonin-dependent inhibition of OT and VP secretion from the rat hypothalamo-neurohypophysial (H-NH) system in vitro.

Material and methods: The H-NH explants were placed in 1 ml of normal Krebs-Ringer (nK-R) buffer and first preincubated for 30 min in control buffer or in the presence of PKA inhibitor, i.e. cAMPS-Rp or H-89. Next, they were incubated in nK-R buffer {fluid F1} and then in buffer as F1 enriched with melatonin (10–9 M or 10–7 M) and/or PKA activator, i.e. cAMP analogue (8-Br-cAMP), or their vehicles {fluid F2}. After 20 min of incubation in fluid F1 and then F2, the media were collected and frozen, to be assayed for OT and VP by the RIA.

Results: 8-Br-cAMP increased OT and VP secretion when the H-NH explants were preincubated in control medium, while PKA inhibitors eliminated its stimulatory effect on OT and VP release. Melatonin (10–7 M) diminished basal OT and VP output from the H-NH system, and inhibited (at both concentrations studied) the cAMP analogue-stimulated release of both neurohormones under control conditions. The effect of melatonin on OT and VP release was completely blocked when cAMPS-Rp, but not H-89, was used to disrupt the cAMP/ /PKA pathway.

Conclusions: Melatonin employs the cAMP/PKA signalling pathway to inhibit OT and VP secretion from the rat H-NH system; nonethe­less, other cAMP-mediated mechanisms are not excluded.

Abstract

Introduction: Melatonin was found to inhibit forskolin-stimulated oxytocin (OT) and vasopressin (VP) release in vitro. The purpose of the present investigation was to evaluate the contribution of the cyclic 3’,5’-adenosine monophosphate/protein kinase A (cAMP/PKA) signalling pathway in melatonin-dependent inhibition of OT and VP secretion from the rat hypothalamo-neurohypophysial (H-NH) system in vitro.

Material and methods: The H-NH explants were placed in 1 ml of normal Krebs-Ringer (nK-R) buffer and first preincubated for 30 min in control buffer or in the presence of PKA inhibitor, i.e. cAMPS-Rp or H-89. Next, they were incubated in nK-R buffer {fluid F1} and then in buffer as F1 enriched with melatonin (10–9 M or 10–7 M) and/or PKA activator, i.e. cAMP analogue (8-Br-cAMP), or their vehicles {fluid F2}. After 20 min of incubation in fluid F1 and then F2, the media were collected and frozen, to be assayed for OT and VP by the RIA.

Results: 8-Br-cAMP increased OT and VP secretion when the H-NH explants were preincubated in control medium, while PKA inhibitors eliminated its stimulatory effect on OT and VP release. Melatonin (10–7 M) diminished basal OT and VP output from the H-NH system, and inhibited (at both concentrations studied) the cAMP analogue-stimulated release of both neurohormones under control conditions. The effect of melatonin on OT and VP release was completely blocked when cAMPS-Rp, but not H-89, was used to disrupt the cAMP/ /PKA pathway.

Conclusions: Melatonin employs the cAMP/PKA signalling pathway to inhibit OT and VP secretion from the rat H-NH system; nonethe­less, other cAMP-mediated mechanisms are not excluded.

Get Citation

Keywords

melatonin, oxytocin, vasopressin, 8-Br-cAMP, cAMPS-Rp, H-89, PKA

About this article
Title

The role of the cAMP/PKA signalling pathway in the inhibitory influence of melatonin on oxytocin and vasopressin secretion from the rat hypothalamo-neurohypophysial system

Journal

Endokrynologia Polska

Issue

Vol 69, No 5 (2018)

Pages

560-566

Published online

2018-08-03

DOI

10.5603/EP.a2018.0051

Pubmed

30074234

Bibliographic record

Endokrynologia Polska 2018;69(5):560-566.

Keywords

melatonin
oxytocin
vasopressin
8-Br-cAMP
cAMPS-Rp
H-89
PKA

Authors

Marlena Juszczak
Anna Krzyminska
Ewa Bojanowska
Magdalena Roszczyk

References (51)
  1. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008; 85(3): 335–353.
  2. Dubocovich ML, Delagrange P, Krause DN, et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010; 62(3): 343–380.
  3. Tosini G, Owino S, Guillaume JL, et al. Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. Bioessays. 2014; 36(8): 778–787.
  4. Sladek CD, Song Z. Diverse roles of G-protein coupled receptors in the regulation of neurohypophyseal hormone secretion. J Neuroendocrinol. 2012; 24(4): 554–565.
  5. Kortus S, Srinivasan C, Forostyak O, et al. Sodium-calcium exchanger and R-type Ca(2+) channels mediate spontaneous [Ca(2+)]i oscillations in magnocellular neurones of the rat supraoptic nucleus. Cell Calcium. 2016; 59(6): 289–298.
  6. Juszczak M, Roszczyk M, Kowalczyk E, et al. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies. J Physiol Pharmacol. 2014; 65(6): 777–784.
  7. Juszczak M, Wolak M, Bojanowska E, et al. The role of melatonin membrane receptors in melatonin-dependent oxytocin secretion from the rat hypothalamo-neurohypophysial system - an in vitro and in vivo approach. Endokrynol Pol. 2016; 67(5): 507–514.
  8. MacKenzie RS, Melan MA, Passey DK, et al. Dual coupling of MT(1) and MT(2) melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochem Pharmacol. 2002; 63(4): 587–595.
  9. Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin--a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011; 93(3): 350–384.
  10. Vanecek J, Watanabe K. Mechanisms of melatonin action in the pituitary and SCN. Adv Exp Med Biol. 1999; 460: 191–198.
  11. Vanĕcek J, Vollrath L. Melatonin inhibits cyclic AMP and cyclic GMP accumulation in the rat pituitary. Brain Res. 1989; 505(1): 157–159.
  12. Almahariq M, Mei FC, Cheng X. Cyclic AMP sensor EPAC proteins and energy homeostasis. Trends Endocrinol Metab. 2014; 25(2): 60–71.
  13. Formosa R, Vassallo J. cAMP signalling in the normal and tumorigenic pituitary gland. Mol Cell Endocrinol. 2014; 392(1-2): 37–50.
  14. Yulia A, Singh N, Lei K, et al. Cyclic AMP Effectors Regulate Myometrial Oxytocin Receptor Expression. Endocrinology. 2016; 157(11): 4411–4422.
  15. Gjertsen BT, Mellgren G, Otten A, et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action. J Biol Chem. 1995; 270(35): 20599–20607.
  16. Song Z, Sidorowicz HE, Sladek CD. cAMP stimulation of vasopressin and oxytocin release and regulation of vasopressin mRNA stability: role of auto-facilitation. J Neuroendocrinol. 2001; 13(2): 158–165.
  17. Greenwood M, Greenwood MP, Mecawi AS, et al. Transcription factor CREB3L1 mediates cAMP and glucocorticoid regulation of arginine vasopressin gene transcription in the rat hypothalamus. Mol Brain. 2015; 8(1): 68.
  18. Roszczyk M, Juszczak M. Forskolin-stimulated vasopressin and oxytocin release from the rat hypothalamo-neurohypophysial system in vitro is inhibited by melatonin. Endokrynol Pol. 2014; 65(2): 125–131.
  19. Van Haastert PJ, Van Driel R, Jastorff B, et al. Competitive cAMP antagonists for cAMP-receptor proteins. J Biol Chem. 1984; 259(16): 10020–10024.
  20. Murray AJ. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal. 2008; 1(22): re4.
  21. Chijiwa T, Mishima A, Hagiwara M, et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990; 265(9): 5267–5272.
  22. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev. 2006; 24(3-4): 261–274.
  23. Leemhuis J, Boutillier S, Schmidt G, et al. The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J Pharmacol Exp Ther. 2002; 300(3): 1000–1007.
  24. Rusnak M, Gainer H. Differential effects of forskolin on tyrosine hydroxylase gene transcription in identified brainstem catecholaminergic neuronal subtypes in organotypic culture. Eur J Neurosci. 2005; 21(4): 889–898.
  25. Garrel G, Lozach A, Bachir LK, et al. Pituitary adenylate cyclase-activating polypeptide stimulates nitric-oxide synthase type I expression and potentiates the cGMP response to gonadotropin-releasing hormone of rat pituitary gonadotrophs. J Biol Chem. 2002; 277(48): 46391–46401.
  26. Ciranna L, Cavallaro S. Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission. Exp Neurol. 2003; 184(2): 778–784.
  27. Costa L, Santangelo F, Li Volsi G, et al. Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus. Hippocampus. 2009; 19(1): 99–109.
  28. Garrel G, Simon V, Thieulant ML, et al. Sustained gonadotropin-releasing hormone stimulation mobilizes the cAMP/PKA pathway to induce nitric oxide synthase type 1 expression in rat pituitary cells in vitro and in vivo at proestrus. Biol Reprod. 2010; 82(6): 1170–1179.
  29. Moteki H, Kimura M, Ogihara M. Activation of extracellular-signal regulated kinase by epidermal growth factor is potentiated by cAMP-elevating agents in primary cultures of adult rat hepatocytes. Biol Pharm Bull. 2011; 34(10): 1542–1552.
  30. Lin HH, Chang SJ, Shie HJ, et al. Ethanol inhibition of NMDA-induced responses and acute tolerance to the inhibition in rat rostral ventrolateral medulla in vivo: Involvement of cAMP-dependent protein kinases. Neuropharmacology. 2006; 51(4): 747–755.
  31. Fu Yu, Han J, Ishola T, et al. PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. Mol Pain. 2008; 4: 26.
  32. Keil MF, Briassoulis G, Stratakis CA. The Role of Protein Kinase A in Anxiety Behaviors. Neuroendocrinology. 2016; 103(6): 625–639.
  33. Ono Y, Saitow F, Konishi S. Differential Modulation of GABAA Receptors Underlies Postsynaptic Depolarization- and Purinoceptor-Mediated Enhancement of Cerebellar Inhibitory Transmission: A Non-Stationary Fluctuation Analysis Study. PLoS One. 2016; 11(3): e0150636.
  34. Juszczak M. Neurokinin A and the neurohypophysial response to melatonin: in vitro studies. J Physiol Pharmacol. 2002; 53(4 Pt 2): 823–834.
  35. Masson-Pévet M, Gauer F, Schuster C, et al. Photic regulation of mt(1) melatonin receptors and 2-iodomelatonin binding in the rat and Siberian hamster. Biol Signals Recept. 2000; 9(3-4): 188–196.
  36. Yasin SA, Grossman A, Forsling ML. Diurnal variation in the effect of melatonin on neurohypophysial hormone release from the rat hypothalamus. Brain Res Bull. 1996; 39(1): 1–5.
  37. Juszczak M. Melatonin affects the oxytocin and prolactin responses to stress in male rats. J Physiol Pharmacol. 1998; 49(1): 151–163.
  38. Taylor SS, Zhang P, Steichen JM, et al. PKA: lessons learned after twenty years. Biochim Biophys Acta. 2013; 1834(7): 1271–1278.
  39. Inoue H, Hase K, Segawa A, et al. H89 (N-[2-p-bromocinnamylamino-ethyl]-5-isoquinolinesulphonamide) induces autophagy independently of protein kinase A inhibition. Eur J Pharmacol. 2013; 714(1-3): 170–177.
  40. Zhang P, Kornev AP, Wu J, et al. Discovery of Allostery in PKA Signaling. Biophys Rev. 2015; 7(2): 227–238.
  41. Ilouz R, Lev-Ram V, Bushong EA, et al. Isoform-specific subcellular localization and function of protein kinase A identified by mosaic imaging of mouse brain. Elife. 2017; 6.
  42. Tocharus C, Puriboriboon Y, Junmanee T, et al. Melatonin enhances adult rat hippocampal progenitor cell proliferation via ERK signaling pathway through melatonin receptor. Neuroscience. 2014; 275: 314–321.
  43. Cheng X, Wan Y, Xu Y, et al. Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits. Mol Med Rep. 2015; 11(1): 99–104.
  44. Liu L, Xu Y, Reiter RJ, et al. Inhibition of ERK1/2 Signaling Pathway is Involved in Melatonin's Antiproliferative Effect on Human MG-63 Osteosarcoma Cells. Cell Physiol Biochem. 2016; 39(6): 2297–2307.
  45. Guo Q, Wang Z, Dong Y, et al. Physiological crosstalk between the AC/PKA and PLC/PKC pathways modulates melatonin-mediated, monochromatic-light-induced proliferation of T-lymphocytes in chickens. Cell Tissue Res. 2017; 369(3): 555–565.
  46. Huete-Toral F, Crooke A, Martínez-Águila A, et al. Melatonin receptors trigger cAMP production and inhibit chloride movements in nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther. 2015; 352(1): 119–128.
  47. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004; 36(1): 1–9.
  48. Reis WL, Biancardi VC, Son S, et al. Carbon monoxide and nitric oxide interactions in magnocellular neurosecretory neurones during water deprivation. J Neuroendocrinol. 2015; 27(2): 111–122.
  49. Dayanithi G, Sabatier N, Widmer H. Intracellular calcium signalling in magnocellular neurones of the rat supraoptic nucleus: understanding the autoregulatory mechanisms. Exp Physiol. 2000; 85 Spec No: 75S–84S.
  50. Dayanithi G, Viero C, Shibuya I. The role of calcium in the action and release of vasopressin and oxytocin from CNS neurones/terminals to the heart. J Physiol Pharmacol. 2008; 59 Suppl 8: 7–26.
  51. Sladek CD, Kapoor JR. Neurotransmitter/neuropeptide interactions in the regulation of neurohypophyseal hormone release. Exp Neurol. 2001; 171(2): 200–209.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl